RGC
ADMA icon

Roberts, Glore & Co’s ADMA Biologics ADMA Stock Holding History

Roberts, Glore & Co’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33,045
Closed -$603K – 217
2025
Q4 		$603K Buy
33,045
+7,335
+29% +$124K 0.16% 119
2025
Q3 		$377K Buy
+25,710
New +$441K 0.1% 155

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Roberts, Glore & Co's ADMA Position: Q1 2026 in Review

Roberts, Glore & Co sold out of ADMA Biologics (ADMA) in Q1 2026, closing a stake of 33,045 shares — an estimated $603K sold.

Roberts, Glore & Co first reported a position in ADMA in Q3 2025 and held it in 2 quarters. The position peaked at $603K in Q4 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Roberts, Glore & Co reported no remaining ADMA Biologics position as of Q1 2026 after selling out during the quarter.
  • Roberts, Glore & Co sold 33,045 ADMA Biologics shares in Q1 2026, an estimated $603K.
  • Roberts, Glore & Co first reported a position in ADMA Biologics in Q3 2025 and held it in 2 quarters.
  • Roberts, Glore & Co's ADMA Biologics position peaked at $603K in Q4 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Roberts, Glore & Co's 13F filing for Q1 2026, filed 4 May 2026.